Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)

This publication has 25 references indexed in Scilit:

• Positron Emission Tomography in Lymphoma: Comparison with Computed Tomography and Gallium-67 Single Photon Emission Computed Tomography
  Clinical Lymphoma, 2000
• Commentary on “Positron Emission Tomography in Lymphoma: Comparison with Computed Tomography and Gallium-67 Single Photon Emission Computed Tomography Imaging”
  Clinical Lymphoma, 2000
• 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
  Annals of Oncology, 2000
• The role of positron emission tomography (PET) in the management of lymphoma patients
  Annals of Oncology, 1999
• Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
  Blood, 1999
• Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma
  Nuclear Medicine Communications, 1998
• Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
  Radiology, 1997
• Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
  European Journal of Nuclear Medicine and Molecular Imaging, 1996
• Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas
  European Journal of Nuclear Medicine and Molecular Imaging, 1995
• Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
  Radiology, 1994